Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $625
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $590 to $625.
Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $590 to $625.